Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$128.81
-0.3%
$126.50
$99.14
$133.10
$326.28B0.388.27 million shs5.90 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.17
+6.0%
$26.88
$25.20
$40.37
$153.85B0.6142.56 million shs97.47 million shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.70%+1.77%-2.09%+6.96%+11.05%
Pfizer Inc. stock logo
PFE
Pfizer
-0.16%-2.70%-7.71%-5.36%-34.69%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.7492 of 5 stars
2.33.03.34.13.22.52.5
Pfizer Inc. stock logo
PFE
Pfizer
4.9794 of 5 stars
3.23.04.24.83.11.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.58
Moderate Buy$131.331.96% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.3333.73% Upside

Current Analyst Ratings

Latest MRK and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$142.00 ➝ $143.00
4/18/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/8/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$140.00 ➝ $143.00
4/5/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/28/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$139.00 ➝ $142.00
3/27/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
3/27/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$130.00 ➝ $135.00
3/22/2024
Pfizer Inc. stock logo
PFE
Pfizer
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/11/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold ➝ Sell$104.00
(Data available from 5/1/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$60.12B5.43$3.01 per share42.77$14.85 per share8.67
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.63$3.16 per share8.61$15.81 per share1.72

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$365M$0.90143.1212.971.673.76%14.15%5.24%8/6/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3675.479.811.163.62%10.88%4.91%5/1/2024 (Confirmed)

Latest MRK and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57$0.82+$0.25N/A$13.87 billion$14.88 billion  
4/25/2024Q1 2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$1.94$2.07+$0.13$2.27$15.21 billion$15.78 billion    
2/1/2024Q4 2023
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.09$0.03+$0.12$0.54$14.49 billion$14.63 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.082.39%+6.08%342.22%13 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.18%+2.57%466.67%15 Years

Latest MRK and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.89
1.25
1.00
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.09%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
72,0002.53 billion2.53 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

MRK and PFE Headlines

SourceHeadline
Why Pfizer Stock Blasted More Than 6% Higher TodayWhy Pfizer Stock Blasted More Than 6% Higher Today
fool.com - May 1 at 5:55 PM
Pfizer Inc. (NYSE:PFE) Shares Sold by New York Life Investment Management LLCPfizer Inc. (NYSE:PFE) Shares Sold by New York Life Investment Management LLC
marketbeat.com - May 1 at 5:46 PM
PFE Earnings: Pfizer Rises After Smashing Q1 EstimatesPFE Earnings: Pfizer Rises After Smashing Q1 Estimates
msn.com - May 1 at 3:39 PM
Pfizer (NYSE:PFE) Stock Price Up 3.8%Pfizer (NYSE:PFE) Stock Price Up 3.8%
marketbeat.com - May 1 at 1:59 PM
Pfizer Stock Gets Boost From Better-Than-Expected EarningsPfizer Stock Gets Boost From Better-Than-Expected Earnings
investopedia.com - May 1 at 1:46 PM
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance RaisedPfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
zacks.com - May 1 at 12:46 PM
Pfizer raises guidance amid cost savingsPfizer raises guidance amid cost savings
msn.com - May 1 at 10:38 AM
Pfizer Stock Rises as Outlook Rises After Earnings BeatPfizer Stock Rises as Outlook Rises After Earnings Beat
finance.yahoo.com - May 1 at 10:38 AM
Pfizer Inc (PFE) Q1 2024 Earnings: Adjusted EPS Surpasses Expectations Amidst Revenue DeclinePfizer Inc (PFE) Q1 2024 Earnings: Adjusted EPS Surpasses Expectations Amidst Revenue Decline
finance.yahoo.com - May 1 at 10:38 AM
Stocks to Watch Wednesday: Starbucks, Pfizer, CVS, AmazonStocks to Watch Wednesday: Starbucks, Pfizer, CVS, Amazon
finance.yahoo.com - May 1 at 10:38 AM
Pfizer raises full-year outlook, stock rises on Q1 beatPfizer raises full-year outlook, stock rises on Q1 beat
finance.yahoo.com - May 1 at 10:38 AM
Pfizer (PFE) Reports Q1 Earnings: What Key Metrics Have to SayPfizer (PFE) Reports Q1 Earnings: What Key Metrics Have to Say
zacks.com - May 1 at 10:35 AM
Pfizer (NYSE:PFE) Releases FY24 Earnings GuidancePfizer (NYSE:PFE) Releases FY24 Earnings Guidance
marketbeat.com - May 1 at 9:35 AM
Pfizer (PFE) Q1 Earnings and Revenues Beat EstimatesPfizer (PFE) Q1 Earnings and Revenues Beat Estimates
zacks.com - May 1 at 8:55 AM
Pfizer revenues fall 19% due to lower COVID-related product demandPfizer revenues fall 19% due to lower COVID-related product demand
proactiveinvestors.com - May 1 at 8:14 AM
Pfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid salesPfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid sales
cnbc.com - May 1 at 7:13 AM
Amazon, Pfizer And 3 Stocks To Watch Heading Into WednesdayAmazon, Pfizer And 3 Stocks To Watch Heading Into Wednesday
benzinga.com - May 1 at 7:01 AM
Pfizer Q1 earnings: non-Covid product sales help post revenues of  $14.9 billion despite Comirnaty, Paxlovid declinePfizer Q1 earnings: non-Covid product sales help post revenues of  $14.9 billion despite Comirnaty, Paxlovid decline
invezz.com - May 1 at 7:01 AM
Pfizer beats profit estimates on cost cuts, RSV vaccine salesPfizer beats profit estimates on cost cuts, RSV vaccine sales
reuters.com - May 1 at 6:50 AM
Pfizer (NYSE:PFE) Trading 0.4% Higher Pfizer (NYSE:PFE) Trading 0.4% Higher
marketbeat.com - April 30 at 3:37 PM
Pfizer and Genmab Receive FDA Approval for Cervical Cancer DrugPfizer and Genmab Receive FDA Approval for Cervical Cancer Drug
baystreet.ca - April 30 at 2:54 PM
Pfizer Q1 Earnings Preview: Covid assets to remain the focus this quarterPfizer Q1 Earnings Preview: Covid assets to remain the focus this quarter
msn.com - April 30 at 2:54 PM
7 Safe Haven Stocks That Can Withstand the Markets Worst Meltdowns7 Safe Haven Stocks That Can Withstand the Market's Worst Meltdowns
investorplace.com - April 30 at 1:50 PM
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
zacks.com - April 30 at 12:21 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Merck & Co., Inc. logo

Merck & Co., Inc.

NYSE:MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.